Introduction: The aim of this study was to analyse 1-and 2-year outcomes aft er photodynamic therapy (PDT) in clinical routine outside of the TAP [treatment of age-related macular degeneration (AMD) with PDT] study. We analysed the func tional results, possible influencing factors and the rate of side effects. Metho ds: We analysed the medical records of 210 consecutive patients between 50 and 9 3 years of age (73±9 years) who had been treated with PDT for active ≥50%clas sic CNV resulting from AMD. Only patients with a minimum follow-up of 1 year (1 27) were included; 52 patients completed 2 years of follow-up. Juxta-and extra foveal CNV were also analysed. Treatment was given in accordance with TAP parame ters and regular follow-up examinations were performed with standardised ETDRS visual acuity (VA) measurements and fluorescein angiography. Results: In the sub foveal group, in 63.6%(70/110) a loss of VA ≥3 lines could be prevented after 1 year, and in 51.1%(23/45) after 2 years. An improvement of ≥1 line was found in 31.8%(1 year) and in 22.2%of eyes (2 years). Severe VA loss of ≥6 lines o ccurred in 10.9%of cases after 1 year and in 15.6%after 2 years. Themean chang e of VA was-1.7±3.4 lines (1 year) and-2.5±3.9 lines (2 years). For the grou p ofCNV with juxta-/extrafoveal localisation, themean change ofVAwas +0.8±2.5 lines after 1 year and +1.0±4.2 lines after 2 years. With regard to different CNV localisations, the results for juxta-/extrafoveal CNV are statistical sign ificantly better (p=0.005 and p=0.035 after 1 and 2 years, respectively). A mean of 2.6 treatments were performed in the first year and 0.5 in the second year. Conclusions: The results obtained in a single institution compare favourably wit h the results of the TAP study. The results regarding functional visual outcome could be obtained with a lower number of treatments in clinical practice. Juxta -and extrafoveal CNV showed significantly better results than a subfoveal local isation of the CNV. In this subgroup a mean improvement of VA could be obtained after 1 or 2 years. Introduction: The aim of this study was to analyze 1-and 2-year outcomes aft er photodynamic therapy (PDT) in clinical routine outside of the TAP [treatment of age-related macular degeneration (AMD) with PDT] study. We analysed the Metho ds: We analysed the medical records of 210 consecutive patients between 50 and 9 3 years of age (73 ± 9 years) who had been treated with PDT for active ≥50 Only patients with a minimum follow-up of 1 year (1 27) were included; 52 patients completed 2 years of follow-up. Juxta-and extra foveal CNV were also analyzed. Treatment was given in accordance with TAP parame ters and regular follow-up examinations were performed with standardized ETDRS visual acuity (VA) measurements and fluorescein angiography. Results: In the sub foveal group, in 63.6% (70/110) a loss of VA ≥ 3 lines could be prevented after 1 year, and in 51.1% (23/45) after 2 year s. An improvement of ≥1 line was found in 31.8% (1 year) and in 22.2% of eyes (2 years). Severe VA loss of ≥6 lines o ccurred in 10.9% of cases after 1 year and in 15.6% after Themean chang e of VA was-1.7 ± 3.4 lines (1 year) and-2.5 ± 3.9 lines (2 years). For the grou p ofCNV with juxta- / extrafoveal localization, themean change of VAwas + 0.8 ± 2.5 lines after 1 year and + 1.0 ± 4.2 lines after 2 years. With regard to different CNV localisations, the results for juxta- / extrafoveal CNV are statistically significantly better (p = 0.005 and p = 0.035 after 1 and 2 years, respectively). A mean of 2.6 treatments were performed in the first year and 0.5 in the second year. Conclusions: The results obtained in a single institution compare favourarably wit h the results of the TAP study. The results regarding functional visual outcome could be obtained with a lower number of treatments in clinical practice. Juxta-and extrafoveal CNV showing significantly better results than a subfoveal local isat ion of the CNV. In this subgroup a mean improvement of VA could be obtained after 1 or 2 years.